- | Aphaia Pharma
After GLP-1, what’s next for weight loss?
A different approach, pursued by Zug, Switzerland-based Aphaia Pharma, is to reawaken nutrient-sensing cells in the distal gut that become less responsive in obesity
- | Elicio Therapeutics
Elicio Merges With Angion to Support Mutant KRAS-Targeted Cancer Vaccine Development
Elicio Therapeutics on Thursday said it closed a previously announced reverse merger
- | Reata Pharmaceuticals
The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree
Reata is a biotech stock with a perfect Relative Strength Rating of 99, putting its 12-month price performance in the top 1% of all stocks, according to IBD Digital.
- | eFFECTOR
Addressing Cancer Therapy Resistance by Targeting Translational Regulation
At the inception of eFFECTOR, one of the key considerations was that, to extend the duration of benefit of a given treatment, you have to contend with resistance. It had become clear that, even when using the most tightly targeted therapy or immunotherapy, resistance happens. I’ve spent about 15 years in the antiviral world working with anti-infectives, mostly antivirals, and we experienced successes with both HIV and hepatitis C by really thinking hard about resistance and anticipating it ahead of time.
- | Umoja Biopharma
Umoja wants to move CAR T beyond the ‘Goldilocks patients’
Umoja wants to offer a solution. The biotech is working on ways to confront all the major limitations of CAR T-cell therapy—the lengthy, pricey manufacturing process and the poor efficacy against solid tumors—with therapies that reengineer a patient’s T cell
- | Ambrx
Resilient Biopharma Leadership With Ambrx’s Dan O’Connor
Since Dan O’Connor stepped in as CEO at Ambrx late last year, the company’s stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O’Connor is no stranger to overcoming adversity.
- | Immunome
Immunome’s Platform Partnership Potential
When I hosted Immunome President & CEO Purnanand Sarma, Ph.D. on episode 104 of the Business of Biotech podcast last summer, the company, like many emerging biotechs, was still wrapped up in rationalizing an application for its antibody technology in the battle against COVID-19.
- | Aphaia Pharma
Sugar pill that’s not a placebo could be key to broad metabolic reset
Swiss biopharma startup Aphaia Pharma AG is taking the concept of “location, location, location” to its extreme. The company started dosing patients in a phase II trial of its lead candidate, Aph-012, in late April, 2023. The trial is a randomized, double-blind, placebo-controlled, multicenter proof-of-concept study to evaluate Aph-012’s ability to improve glucose tolerance in individuals with prediabetes, as measured by a pathological oral glucose tolerance test. In another phase II trial, Aph-012 is being tested as a weight loss drug for individuals with a BMI between 30 and 40. Aph-012’s active ingredient? Glucose. But delivered exactly to the right place.
